Pinetree

• 목록
• 답변
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medication during pregnancy and nursing is challenging for women with the condition. There is a lack of information about how long-term exposure to these medications can affect the fetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological issues like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge that further high-quality studies are needed.

Risk/Benefit Analysis

Women who are pregnant and taking adhd over the counter Medication uk medication need to consider the benefits of taking it versus the dangers for the baby. Doctors don't have the necessary data to make unequivocal recommendations but they can provide information regarding the risks and benefits to help pregnant women make informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during their early pregnancy were not at a greater risk of fetal malformations, or structural birth defects. Researchers used a vast population-based study of case-control to determine the prevalence of major structural birth defects in babies born to mothers who took stimulants during the early stages of pregnancy, and those who did not. Clinical geneticists and pediatric cardiologists examined the cases to ensure accurate case classification and to limit the chance of bias.

The study of the researchers was not without its limitations. The most important issue was that they were unable to distinguish the effects of the medication from those of the underlying disorder. That limitation makes it difficult to determine whether the limited associations observed in the groups that were exposed are due to the use of medication or confounding by comorbidities. In addition, the researchers did not examine the long-term effects of offspring on their parents.

The study did reveal that infants whose mothers took ADHD medications during pregnancy were at slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than those whose mothers had not taken any medication or had taken off their medication prior to or during pregnancy. This was due to central nervous system disorders, and the higher risk of admission did not appear to be affected by the type of stimulant medication was used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having to have a caesarean section or one whose baby scored low on the Apgar scale (less than 7). These increases did not appear to be influenced by the kind of medication used during pregnancy.

The research suggests that the risk of a small amount with the use of ADHD medications during early pregnancy could be offset by the greater benefit to both mother and child of continuing treatment for the woman's condition. Physicians should discuss the issue with their patients and, when they are able, assist them in developing strategies to improve coping skills that can lessen the impact of her disorder on her daily life and relationships.

Interactions with Medication

Many doctors are confronted with the dilemma of whether to continue treatment or stop during pregnancy as more women are diagnosed with ADHD. These decisions are often made without clear and authoritative evidence. Instead, physicians must consider their own expertise and experience, as well as the experiences of other doctors and the research that has been conducted on the subject.

Particularly, the issue of potential risks for the infant can be difficult. The research that has been conducted on this topic is based on observation instead of controlled studies and a lot of the results are conflicting. In addition, most studies limit their analysis to live births, which could underestimate severe teratogenic effects that cause abortion or termination of the pregnancy. The study presented in this journal club addresses these limitations by examining data on both live and deceased births.

The conclusion The conclusion: While some studies have shown that there is a positive correlation between ADHD medications and the risk of certain birth defects, others have found no such relationship, and most studies have a neutral or slight negative effect. In the end, a careful risk/benefit analysis is required in every case.

For many women with ADHD, the decision to stop medication is difficult if not impossible. In fact, in a recent article in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can cause depression, feelings of isolation and family conflict for those suffering from the disorder. The loss of medication can also affect the ability to safely drive and to perform work-related tasks which are crucial aspects of everyday life for those suffering from ADHD.

She suggests that women who are unsure about whether or not to stop taking medication because of their pregnancy consider informing family members, friends and colleagues about the condition, its effects on daily life, and the advantages of continuing the current treatment regimen. It can also help women feel supported in her decision. It is important to remember that some drugs can pass through the placenta so if the patient decides to stop her ADHD medication during pregnancy and breastfeeding, she should be aware of the possibility that traces of the drug can be transferred to the infant.

Birth Defects Risk

As the use and misuse of ADHD medications to treat the symptoms of attention deficit disorder hyperactivity disorder (ADHD), increases the concern over the potential effects of these drugs on foetuses. Recent research published in the journal Molecular Psychiatry has added to the body knowledge on this issue. With two massive data sets researchers were able analyze more than 4.3 million pregnancies to determine whether stimulant medication use increased the risk of birth defects. Although the risk overall remains low, the researchers discovered that the first-trimester exposure to ADHD medications was linked to an increase in the risk of certain heart defects, such as ventriculo-septal defect (VSD).

The authors of the study didn't discover any connection between the use of early medications and congenital anomalies like facial deformities or club feet. The results are consistent with previous studies revealing a small but significant increase in the risk of heart malformations in women who started taking ADHD medications before pregnancy. This risk increased during the latter stages of pregnancy when a large number of women stopped taking their medication.

Women who took ADHD medication in the first trimester of their pregnancy were also more likely to have a caesarean section, a low Apgar score after delivery and a baby who needed breathing assistance at birth. However, the authors of the study were unable to eliminate bias due to selection by limiting the study to women who did not have other medical issues that could have contributed to the findings.

Researchers hope their research will inform physicians when they meet pregnant women. The researchers recommend that while discussing the risks and benefits are important, the choice regarding whether or not to stop medication should be based on the severity of each woman's ADHD symptoms and her needs.

The authors caution that, even though stopping the medication is a possibility to consider, it is not recommended due to the high rate depression and other mental disorders for women who are pregnant or recently gave birth. Additionally, the research suggests that women who choose to stop taking their medication are more likely to have a difficult time getting used to life without them following the birth of their baby.

Nursing

It can be a challenge to become a mother. Women who suffer from ADHD who have to manage their symptoms while attending doctor appointments and making preparations for the arrival of a baby and adapting to new routines in the home can experience severe challenges. Therefore, many women decide to continue taking their ADHD medications throughout the course of pregnancy.

The risk for nursing infant is low because the majority of stimulant medication is absorbed through breast milk in low amounts. However, the frequency of exposure to medication by the newborn may differ based on dosage, how often it is taken and at what time it is administered. Additionally, different medications enter the baby’s system via the gastrointestinal tract or through breast milk. The effect on the health of a newborn isn't fully known.

Some doctors may stop taking stimulant medication during a woman’s pregnancy due to the lack of research. It's a difficult choice for the woman, who must weigh the benefits of her medication against the potential risks to the embryo. As long as there is no more information, doctors should ask all pregnant patients about their experience with ADHD and if they plan or are taking to take medication during the perinatal period.

Numerous studies have proven that women can continue taking their ADHD medication safely while breastfeeding and during pregnancy. In response, a rising number of patients are opting to do so. They have found, in consultation with their doctor, that the benefits of retaining their current medication outweigh any possible risks.

Women with adhd stimulant medication who are planning to nurse should seek advice from a specialist psychiatrist prior to becoming pregnant. They should discuss their medication with their prescriber, and the pros and cons of continuing treatment. This includes non-pharmacological methods. Psychoeducation should also be provided to help pregnant women suffering from ADHD be aware of their symptoms and the underlying disorder, learn about available treatment options and strengthen existing coping strategies. This should involve a multidisciplinary approach with the GP, obstetricians and psychiatry. The pregnancy counselling should consist of discussion of a management plan for both the mother and child, and monitoring for signs of deterioration and, if necessary, adjustments to the medication regimen.